Anaplastic glioma · 9 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Carboplatin and Bevacizumab Variant #01 | — | R 20 420 | 28d | — | — | ~2 | ~R 40 840 indirect | — |
Irinotecan and Bevacizumab Variant #01 | — | R 19 987 | 14d | — | — | ~2 | ~R 39 975 indirect | — |
Bevacizumab monotherapy Variant #01 | — | R 19 082 | 14d | — | ~9.0 mo | ~52 | ~R 992 271 PFS proxy · indirect | 2 |
Temozolomide monotherapy Variant #02 | — | R 7 358 | 14d | — | ~8.6 mo | ~26 | ~R 129 994 PFS proxy · indirect | 1 |
Irinotecan monotherapy Variant #01 | — | R 2 716 | 42d | ~2.3 mo | ~8.5 mo | ~11 | ~R 29 874 PFS proxy · indirect | 19 |
Cyclophosphamide monotherapy Variant #01 | — | R 1 680 | 28d | — | ~15.8 mo | ~1 | ~R 1 680 PFS proxy · indirect | 1 |
Etoposide monotherapy Variant #01 | — | R 1 231 | 28d | — | — | ~6 | ~R 7 386 indirect | — |
PCV Variant #02 Partial | — | R 327 | 56d | — | ~49.8 mo | ~6 | ~R 1 959 PFS proxy · indirect | 2 |
Radiation therapy N/A - radiation | — | — | 49d | ~46.0 mo | ~7.5 mo | — | — | 8 |
9 of 9 regimens shown